Nuvalent
Biotechnology
Nuvalent is a clinical-stage biopharmaceutical company developing precisely targeted kinase-inhibitor therapies for patients with cancer, with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). Using structure-based drug design, it develops small molecules designed to overcome kinase resistance and improve target selectivity.
- Zidesamtinib (ROS1 inhibitor for ROS1-positive NSCLC)
- Neladalkib (ALK inhibitor for ALK-positive NSCLC; NDA accepted with FDA Priority Review, PDUFA date November 27, 2026)
- Pipeline of multiple discovery-stage research programs
Open roles at Nuvalent
3 matching roles
Remote
Remote eligibility: Eligibility not captured
Manager
$195k to $215k USD / year
- Management Occupations
- Sales
Posted 1 month ago
Source: Greenhouse
Remote
Remote eligibility: Eligibility not captured
Director
$216k to $252k USD / year
- Management Occupations
- Marketing
Posted 3 months ago
Source: Greenhouse
Remote
Remote eligibility: Eligibility not captured
Director
$230k to $260k USD / year
- Management Occupations
- Medical Strategy
Posted 1 month ago
Source: Greenhouse
Showing 3 of 3 roles